Overview

Intravenous DNase I for the Treatment of Sepsis (IDEALSepsisI)

Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
Phase I dose-escalation safety and feasibility of IV DNase I in ICU septic patients.
Phase:
Phase 1
Details
Lead Sponsor:
McMaster University
Collaborator:
Canadian Institutes of Health Research (CIHR)